FK 23

Drug Profile

FK 23

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator Unknown
  • Developer Nichi-Nichi Pharmaceutical Co.; Nonindustrial source
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Immunosuppression; Neutropenia

Most Recent Events

  • 05 Jun 2001 No-Development-Reported for Neutropenia in Japan (Unknown route)
  • 05 Jun 2001 No-Development-Reported for Immunosuppression in Japan (Unknown route)
  • 23 Sep 1998 A preclinical study has been added to the Immunological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top